Drug deals in 2006: cutting edge legal and regulatory issues in the pharmaceutical industry.
Set amidst the backdrop of rising prescription drug costs and a renewed governmental commitment to combating fraud, this article highlights recent enforcement actions against the pharmaceutical industry. In an effort to clarify today's turbulent regulatory landscape, the authors also explore the elements of a successful compliance program for pharmaceutical manufacturers and identify the major areas of concern for the future.